This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Synthesis of Bridged Pyrimidine Nucleosides and Triazo [4, 3-c] Pyrimidine Nucleoside Analogues

Stefania Barbato^a; Gennaro Piccialli^a; Ciro Santacroce^a; Lorenzo De Napoli^b; Luciano Mayol^b
^a Dipartimento di Chimica Organica e Biologica, Università di Napoli, Napoli, Italy ^b Dipartimento di Chimica della Sostanze Naturali, Università di Napoli, Napoli, Italy

To cite this Article Barbato, Stefania , Piccialli, Gennaro , Santacroce, Ciro , De Napoli, Lorenzo and Mayol, Luciano(1991) 'Synthesis of Bridged Pyrimidine Nucleosides and Triazo [4, 3-c] Pyrimidine Nucleoside Analogues', Nucleosides, Nucleotides and Nucleic Acids, 10: 4, 853 — 866

To link to this Article: DOI: 10.1080/07328319108046666 URL: http://dx.doi.org/10.1080/07328319108046666

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF BRIDGED PYRIMIDINE NUCLEOSIDES AND TRIAZO [4,3-c] PYRIMIDINE NUCLEOSIDE ANALOGUES

Stefania Barbato, Gennaro Piccialli and Ciro Santacroce

Dipartimento di Chimica Organica e Biologica, Università di Napoli, Via Mezzocannone 16, 80134 Napoli-Italy

Lorenzo De Napoli and Luciano Mayol*

Dipartimento di Chimica della Sostanze Naturali, Università di Napoli, Via D.Montesano 49, 80131 Napoli-Italy

ABSTRACT

The synthesis and the spectral characterization of a number of N^4-N^4 bridged pyrimidine nucleosides and triazo [4,3-c] pyrimidine nucleoside analogues are reported.

INTRODUCTION

Naturally occurring pyrimidine nucleosides and their derivatives play a very important role in the life of a cell and, therefore, it is not surprising that various pyrimidine nucleoside analogues exhibit important biological properties, such as anticancer and/or antiviral activity, inhibiting the DNA synthesis or interfering with enzymes of the nucleic acids metabolism $^{1-3}$.

As a part of our studies on pyrimidine nucleoside analogues $^{4-6}$, we wish to report here the chemical synthesis and spectroscopic characterization of compounds 5-18.

The bridged nucleosides 7-14, could be of interest as models for studies of enzyme inhibition mechanism to explain the anticancer activity of certain alkylating bifunctional

$$R_3$$

$$R_2O$$

$$OR_2$$

$$15 - 18$$

HO
$$R_2$$
 R_1 R_1 R_1 R_1 R_2 R

Compound	R ₁	R_2
<u>7</u>	СН3	∞ 3
<u>8</u>	Н	∞ aн ₃
<u>9</u>	СН3	Н
10	Н	Н

 $agents^{7-9}$. Moreover, studies concerning the effect on the growth of the neuroblastoma cells and on DNA synthesis, in order to evaluate the therapeutic potential of the new compounds are currently in progress.

As for the triazo[4,3-c] pyrimidine nucleosides 15-18, it is to be noted that nucleoside analogues which show an alterated nitrogen pattern are of wide biological interest 10. In fact, the structural similarity of 15-18 with purine nucleosides could enable them to emulate or antagonize the biological functions of naturally occurring metabolites of this class. Particularly, we are going to synthesize oligodeoxyribonucleotides which incorporate compounds 16-18 in the recognition sequence of endodeoxyribonucleases with the aim of studying the interaction of the resulting oligomers with the pertinent enzymes 11,12.

Our approach to the synthesis of compounds 7-18 involves in the first step the reaction of the chlorinated compounds 1^4 and 2^5 with the appropriate nucleophilic reagent.

 5^8 , $1-(2-\text{deoxy}-\beta-D-\text{ribofuranosyl})-4-(2-\text{aminoethyl})-\text{aminopyrimidin}-2(1H)-\text{one}$, as well as 3^6 , $1-(2-\text{deoxy}-\beta-D-\text{ribo-furanosyl})-4-[(2-\text{aminoethyl})\text{amino}]-5-\text{methylpyrimidin}-2(1H)-\text{one}$, was prepared starting from 2 by reaction with ethylenediamine. This reagent also causes the aminolysis of the ester functions. The preparation of the hydrazino derivatives 4^6 , $1-(2-\text{deoxy}-\beta-D-\text{ribofuranosyl})-4-\text{hydrazino}-5-\text{methylpyrimidin}-2(1H)-\text{one}$, and 6, $1-(2-\text{deoxy}-\beta-D-\text{ribofuranosyl})-4-\text{hydrazino}-$ pyrimidin-2(1H)-one, involved 1 and 2 as well, through the reaction with anhydrous hydrazine which causes the concomitant hydrazinolysis of the acetates. In the case of the bridged nucleosides 1 and 10 compounds 11 and 12 were reacted with 12 and 13 and 13 respectively in dimethylformamide at room

Table 1. - 1 H NMR (250 MHz) Chemical shifts * (δ) of compounds 7-14

								•	
Positio	$\frac{7}{n \text{ CD}_3}$	OD	<u>8</u> C ₅ D ₅ N	<u>9</u> CD ₃ OD	10 C ₅ D ₅ N	11 CD ₃ OD	12 C ₅ D ₅ N	C ₅ D ₅ N	14 C ₅ D ₅ N
	J		, ,	3	, ,	J))	, ,	, ,
			6.12 d				5.92 d		
5					5.96 d				5.83 d
			6.11 d				5.85 d		
	7.80	bs	8.32 d			7.25 bs	7.79 d		
6				7.77 bs	8.28 d			7.59 bs	7.76 d
	7.49		7.85 d			6.97 bs	7.28 d		
	1.97	S				1.95 bs			
CH ₃				1.95 bs				1.72 bs	
,	1.95	bs				1.95 bs			
A	6.29	m	6.96 dd			6.30 dd	6.97 dd		
1'				6.29 dd	7.03 dd			7.00 dd	6.98 dd
3	5.29	dd	6.74 dd			6.26 dd	6.66 dd		
Α	2.35	m	2.88-			2.22 m	2.60-		
	2.52	m	-2.37	2.17 m	2.54 π		-2.37		
2'			comp.	2.35 m	2.76 m		comp.	2.53 m	2.51 m
			sign.				sign.		
В	2.25	m				2.27 m			
Α	4.39	m	5.00 m			4.43 m	4.95 m		
3 1				4.42 m	4.97 m			4.98 m	4.96 m
В	5.28	m	5.45 m			5.27 m	5.43 m		
Α	3.95	m	4.42 m			3.91 m	4.43 m		
4'				3.95 m	4.47 m			4.43 m	4.43 m
8	4.30	m	4.49 m			4.26 m	4.35 m		
Α	3.81		4.20 m			3.78 m	4.13 m		
5'				3.31 m	4.13 m			4.13 m	4.12 m
В	4.40	m	4.56 m			4.36 m	4.51 m		
	2.13		2.30 s			2.16 s	2.03 s		
2CH3C0							- -		
3	2.12	s	2.00 s			2.12 s	1.99 s		
CH ₂ CH ₂				3.70 bs	3.90 s	22			

^{*} The assignments of the signals of the sugar moieties A and B were supported by extensive spin decoupling experiments.

temperature for 10 hrs. The bridged nucleosides $\underline{11}$ and $\underline{12}$ were synthesized by reaction of $\underline{1}$ and $\underline{2}$ with $\underline{4}$ and $\underline{6}$ respectively in dimethylformamide at 0°C for 8 hrs. Compounds $\underline{7}$, $\underline{8}$, $\underline{11}$ and $\underline{12}$ were purified by silica gel chromatography and their structures confirmed by elemental analyses and spectral data [MS, 1 H and 13 C NMR (Tables 1-2), UV].

Particularly, in the case of <u>11</u> and <u>12</u>, the UV spectra displayed a very large bathochromic shift in comparison with the starting material, thus indicating the presence of a highly conjugated system.

Table 2.	_	¹³ c	NMR	(62.	. 9	MHz)	Chemical	shifts	(δ)	of	compounds	7-14	3
·		_		,		,				• ,	~ -		, , ,	

	<u>7</u>		9	10 (CD ₃	11	12	13	14
Position	CD3OD	C_D_N	1 CD ₃ OD	(CD3) ₂ SO	12 C ₅ D ₅ N	13 C ₅ D ₅ N	14 C ₅ D ₅ N
	•	, ,	-	,	2 3	, ,	, ,	, ,
	165.4	164.9			151 2			
2	10).4	104.9	165.5	163.4	151.3	b	ъ	_
4	165.3	164.8	10).)	103.4	151.2	Ų	U	Ъ
	159.3	157.3				140.0		
4	173.3	17/.3	158.4	155 0	149.5	149.0	140 6	4.47.0
4	158.4	156 7	150.4	155.0	1.40	1.47 0	148.6	147.8
		156.7			149.0	147.9		
_	105.3	96.4			111.3	102.3		
5			104.8	94.7			109.0	101.7
	104.8	95.9			110.7	101.4		
	138.9	140.8			131.1	134.0		
6			138.9	139.9			130.7	132.6
	137.8	139.6			129.9	132.4		
	13.2				13.2			
CH ₃			13.1				12.8	
3	13.1				13.1			
	88.7	88.9			88.4	88.6		
1 '			88.8	87.1			88.6	88.8
	87.4	86.9		•	85.7	85.3		
	41.9	42.2			40.5	40.8		
2'		· -	41.9	40.4	, , , ,	,	40.7	40.9
=	38.6	38.1	1	10.7	37.1	36.7	70.7	70.7
	87.4	86.9			85.7	85.3		
3'	57.7	00.9	97 5	84.8	07.7	07.3	05.0	05.0
ی	83.6	82 7	87.5	04.0	02.4	90.0	85.2	85.2
		82.7			83.1	82.2		
4'	72.0	71.4	70.0	70.6	72.4	71.7		
4.	75.0	.	72.0	70.3			71.7	71.9
	75.9	75.2			75.9	74.9		
. .	62.8	62.5			63.1	62.6		
5'			62.9	61.3			62.6	62.7
	65.0	64.5			65.1	64.4		
	20.7	20.7			20.8	20.6		
2 <u>С</u> н ₃ со								
3	20.7	20.6			20.8	20.5		
	41.8	40.9						
CH ₂ CH ₂			41.9	Ъ				
2 2	41.8	40.9	•					
	172.0	170.5			172.2	170.3		
2СН ₃ <u>С</u> О					.,	.,		
-3 - -	172.0	170.5			172.2	170.3		
	,	.,			1/6.6	1/0.3		

a. confirmed by DEPT experiments.

Compounds 7, 8, 11 and 12 were deacetylated by treatment with a solution of MeOH/concentrated ammonia (1:1) at room temperature for 12 hrs under stirring to give $9,10^8,13$ and 14 respectively, in almost quantitative yields (NMR:Tables 1-2).

b. submerged by the solvent signals.

Table 3. - 1 H NMR (250 MHz) a and 13 C NMR (62.9 MHz) b Chemical shifts of compounds $\underline{15}$ -18.

	15		16		17		18	
	-8 0	<u>9</u> H	8 c	δн	δ _C	94	9 <u>c</u>	δH
Position	CDC1 ₃	CDC13	CD3OD	CD3OD	CD30D	CD3OD	CD3OD	C ₅ D ₅ N
3	1.15.5	·	156.1		155.2	8.37 s	155.2	8.39 s
5	150.5		165.5		155.9		é	
7	124.4	6.98 bs	131.6	8.00 bs	131.5	8.03 bs	133.5	8.26 d
8	106.9		106.6		107.1		96.9	6.85 d
9	149.2		145.9		146.3		154.0	
CH ₂ -3	13.10	2.90 s	14.9d	2.54 s				
CH ₃ -3 CH ₃ -8	12.9c	2.38 bs	13.0d	2.31 bs	13.0	2.34 bs		
1,3	85.6	6.44 dd	89.4	6.53 dd	89.4	6.54 dd	90.0	6.56 do
		2.23 m		2.49 m		2.37 m		2.38 m
2'	37.7		41.9		41.9		42.2	
		2.52 m		2.52 m		2.47 m		2.51 m
3'	82.5	5-26 m	87.9	4.50 m	88.0	4.52 m	87.5	4.49 m
4'	74.0	4.31 m	72.0	4.03 m	71.9	4.04 m	71.2	4.07 mt
5'	63.5	4.40 m	62.7	3.86 m	62.6	3.87 m	62.0	3.85 m
	20.7	2.13 s						
CH3CO								
- 3	20.7	2.15 s						
	170.0							
сн ₃ со								
3-	170.1							

a. confirmed by spin decoupling experiments.

The syntheses of the triazo[4,3-c pyrimidine] nucleosides 15-18 were performed by reaction of the hydrazino derivatives 4 and 6 with acetic anhydride (pyridine, room temperature, 2 hrs), or acetic formic anhydride (pyridine, 0°, 3 hrs) and deacylation according to the scheme.

In the case of the formyl derivatives, no intermediate purification step was included between the two reactions. The triazo [4,3-c] pyrimidine nucleosides were purified by silica gel chromatography and the structures were confirmed by elemental analyses and spectral data $[MS, \ ^1H \ and \ ^{13}C \ NMR \ (Table 3), UV]$.

b. confirmed by DEPT experiments.

c. and d. assignments with identical superscript may be reversed.

e. submerged by solvent signals.

Scheme

In this paper we have further proved the versatility of the chlorine derivatives $\underline{1}$ and $\underline{2}$ as synthons for the preparation, in very satisfactory yields, of a large variet/ of pyrimidine deoxyribonucleosides C-4 substituted. Particularly, it is noteworth that the use of compounds $\underline{1}$ and $\underline{2}$ furnishes an alternative approach to the previously reported synthesis 7,8 of bridged nucleosides.

EXPERIMENTAL

General procedure

All the reagents for the syntheses are commercially available (Merck). The $^{1}{\rm H}$ and $^{13}{\rm C}$ NMR Fourier transform spectra were recorded with a Bruker WM-250 instrument. The UV spectra were taken on a Perkin-Elmer 550S spectrophotometer. MS were taken on a Kratos MS 50 instrument. Chemical

shifts were expressed in p.p.m. on the respect of the residual solvent signal. Optical rotations were measured with a Perkin-Elmer 141 polarimeter at 25°C.

1-(2-Decxy-ß-D-rybofuranosyl)-4-(2-aminoethyl)-aminopyrimidin-2(1H)-one (5)

Compound 2 (200 mg, 0.61 mmol) was treated with excess of freshly distilled anhydrous ethylenediamine at room temperature for 5 hrs. The reaction mixture, dried in vacuo, was purified by PLC (silica gel 0.5 mm, eluent EtOH/H₂O/concentrated ammonia, 80:16:4). The band R_{f} 0.4 (UV light) eluted with MeOH afforded 120 mg of 5 (78 % yield). Recrystallization from MeOH gave an analytically pure sample m.p. 145-148°; $[\alpha]_D$ = 51.4° (c = 1 in MeOH). Anal. Calcd. for $C_{13}H_{18}N_{4}O_{4}$: C, 48.88; H, 6.71; N, 20.73. Found: C, 48.99; H, 6.73; N, 20.69. UV (λ max in MeOH) 273 nm (ϵ = 8500). CI MS gave significant ions at m/z: 271 (MH) $^+$, 155 (M-sugar residue+2H) $^{+}$. 1H NMR (CD₃OD) : δ 7.92 (1H, d, H-6), 6.30 (1H, dd, H-1'), 5.90 (1H, d, H-5), 4.39 (1H, m, H-3'), 3.97(1H, m, H-4'), 3.78 (2H, m, H_2-5'), 3.46 (2H, t, $-CH_2-CH_2 -NH_2$), 2.83 (2H, t, $-CH_2-CH_2-NH_2$), 2.26 (1H, m, H_a-2'), 2.18 (1H, m, H_b-2'). ¹³C NMR (CD₃OD): δ 165.9 (C-2), 158.6 (C-4), 141.2 (CH-6), 97.1 (CH-5), 88.8 (CH-1'), 87.5 (CH-3'), 72.1 (CH-4'), 62.9 (CH_2-5') , 44.2 and 42.1 $(-CH_2-CH_2-NH_2)$, 41.8 (CH₂-2').

1-(2-Deoxy-B-D-ribofurancsyl)-4-hydrazinopyrimidin-2(1H)-one

Compound 2 (200 mg, 0.61 mmol) was treated with excess of anhydrous hydrazine at room temperature for 2 hrs. The resulting solution was dried in vacuo and dissolved in MeOH.

The crude mixture was chromatographed by PLC (silica gel 0.5 mm, eluent 1-butanol/acetic acid/water, 60:15:25); the band R_f 0.20 (UV light) eluted with MeOH afforded 120 mg of 6 (90% yield) as a white amorphous solid; $\left[\alpha\right]_D = 35^\circ$ (c = 0.8 in MeOH). Anal. Calcd. for C₉H₁₄N₄O₄: C, 44.62; H, 5.83; N, 23.13. Found: C, 44.73; H, 5.71; N, 23.22. UV ($\lambda_{\rm max}$ in MeOH) 274 nm (ϵ =6500). CI MS gave significant ions at m/z: 243 (MH)⁺, 127 (base moiety+2H)⁺, 81 (sugar moiety-2H₂O)⁺. ¹H NMR (CD₃OD): δ 8.19 (d, 1H, H-6), 6.25 (1H, d, H-5), 6.03 (1H, dd, H-1'), 4.40 (1H, m, H-3') 3.98 (1H, m, H-4'), 3.78 (2H, m, H₂-5'), 2.35 (2H, m, H₂-2'). ¹³C NMR (CD₃OD): δ 157.3 (C-4), 145.6 (CH-6), 98.6 (CH-5), 89.5 (CH-1'), 88.4 (CH-3'), 72.3 (CH-4'), 63.0 (CH₂-5'), 41.9 (CH₂-2'), (C-2 not observed).

Synthesis of 7(8)

A solution of the chlorine derivative $\frac{1}{2}$ (0.5 mmol) and $\frac{3}{5}$ (0.5 mmol) in anhydrous dimethylformamide (7 ml) was stirred at room temperature for 10 hrs. Removal of the solvent in vacuo yielded a residue which was purified by PLC (silica gel 0.5 mm, eluent CHCl $_3$ /MeOH 85:15); the band R $_f$ 0.35 (0.30) (UV light), eluted with CHCl $_3$ /MeOH (7:3), afforded the products $\frac{7}{5}$ (8).

7: 82 % yield, m.p. 128-130° (from ethyl acetate/ $CHCl_3$); $[\alpha]_D$ =43.0° (c = 0.8 in MeOH).Anal. Calcd. for $C_{26}^H _{36}^N _{60}^O _{10}$: C, 52.69, H, 6.12, N, 14.18. Found: C, 52.81, H, 6.14, N, 14.16. UV (λ_{max} in MeOH) 281 nm (ϵ = 22000). FAB MS gave significant ions at m/z: 593 (MH)⁺, 477 (M-deacetylated sugar+2H)⁺, 277 (M-sugar residues +3H)⁺.

8: 79% yield, m.p. 187-189° (from MeOH); $[\alpha]_D$ + 65.4° (c = 1 in MeOH). Anal. Calcd. for $C_{24}^H_{32}^N_{6}^O_{10}$: C, 51.06; H, 5.71;

N,14.89. Found: C, 51.10; H, 5.66; N, 14.77. UV (λ_{max} in MeOH) 274 nm (ϵ = 22000). FAB MS gave significant ions at m/z: 565 (MH)⁺; 449 (M-deacetylated sugar+2H)⁺, 365 (M-diacetylated sugar+2H)⁺, 249 (M-sugar residues+3H)⁺.

Synthesis of 11 (12)

A solution of the chlorine derivatives $\underline{1}$ ($\underline{2}$) (0.5 mmol) and $\underline{4}$ ($\underline{6}$) (0.5 mmol) in anhydrous dimethylformamide (7 ml) was stirred at 0°C for 8 hrs. After removal of the solvent $\underline{\text{in vacuo}}$, the solid residue was purified by PLC (silica gel 0.5 mm, eluent CHCl $_3$ /MeOH 85:15). The band R $_f$ 0.4 (0.3) (UV light) eluted with CHCl $_3$ /MeOH (3:2) afforded the compound $\underline{11}$ ($\underline{12}$).

11: 75% yield; m.p. 113-115° (from benzene); $[\alpha]_D = -11.7^\circ$ (c = 1 in MeOH). Anal. Calcd. for $C_{24}^H_{32}^N_{6}^{0}_{10}$: C, 51.06; H, 5.71; N, 14.89. Found: C, 51.15; H, 5.70; N, 14.98. UV (λ max in MeOH) 378 nm (ϵ = 12700), 359 (25800), 342 (28500), 332 (22600), 246 (8600); FAB MS gave significant ions at m/z: 565 (MH)⁺, 448 (M-deacetylated sugar+H)⁺.

<u>12</u>: 70% yield; m.p. 126-127° (from MeOH); $[\alpha]_D = 4.5$ ° (c = 1 in MeOH). Anal. Calcd. for $C_{22}^H {}_{28}^N {}_{6}^O {}_{10}$: C, 49.25; H, 5.26; N, 15.67. Found: C, 49.10; H, 5.30; N, 15.73. UV (λ_{max} in MeOH) 379 nm (s), 362 nm (ϵ = 17000), 344 (19500), 330 (s), 256 (7400). FAB MS gave significant ions at m/z : 537 (MH)⁺, 420 (M-deacetylated sugar+H)⁺.

Deacetylation of 7, 8, 11 and 12

Compounds 7, 8, 11 and 12 were treated with excess of a solution of concentrated ammonia/MeOH (1:1) at room temperature for 12 hrs under stirring. After removal of the solvent in vacuo the resulting mixture was dissolved in water and

lyophilized. TLC analyses and spectroscopic data indicated that the starting compounds had been completely converted into the deacetyl derivatives $\underline{9}$, $\underline{10}$, $\underline{13}$ and $\underline{14}$ respectively in almost quantitative yields.

9: m.p. 195-197° (from MeOH); $[\alpha]_D$ 63.6° (c = 1 in MeOH). Anal. Calcd. for : $C_{22}^H_{32}^N_{60}^0_8$: C, 51.96; H, 6.34; N, 16.53. Found C, 51.84; H, 6.30, N, 16.48. UV (λ max in MeOH), 280 nm (ϵ = 20000). FAB MS gave significant ions at m/z : 509 (MH)⁺, 393 (M-deacetylated sugar+2H)⁺, 277 (M-sugar residues+3H)⁺.

 $\underline{10}$: amorphous solid; $[\alpha]_D$ = 36.0 (c = 1 in MeOH). Anal. Calcd. for $C_{20}^H 28^N 6^0 8$: C, 49.99; H, 5.88; N, 17.49. Found: C, 50.12; H, 5.94; N, 17.35. UV (λ_{max} in MeOH) 275 nm (ϵ = 16000). FAB MS gave significant ions at m/z : 481 (MH)⁺, 249 (M- sugar residues+3H)⁺.

13: m.p. 195-198° (from EtOH); [α]_D = 3.4° (c = 1 in MeOH). Anal. Calcd for $C_{20}^{H}_{28}^{N}_{6}^{O}_{8}$: C, 49.99; H, 5.88; N, 17.49. Found: C, 50.07; H, 5.98; N, 17.39. UV (λ in MeOH) 379 nm, (ϵ =11000), 359 (22000), 343 (23800), 331 (19200), 248 (7800). FAB MS gave significant ions at m/z: 481 (MH)⁺, 365 (M-deacetylated sugar+2H)⁺.

Synthesis of $6-(2-\text{deoxy}-3,5-\text{di}-0-\text{acetyl}-\beta-D-\text{ribofuranosyl})-3,8-\text{dimethyltriazo}$ [4,3-c] pyrimidin-5(6H)-one (15).

200 mg of $\underline{4}$ were treated with excess of acetic anhydride (3 ml) in dry pyridine (6 ml) for 2 hrs at room temperature.

After removal of the solvent in vacuo, the residue was chromatographed by PLC (silica gel 0.5 mm, eluent CHCl $_3$ /MeOH 96:4); the band R $_f$ 0.5 (UV light) eluted with CHCl $_3$ /MeOH (7:3) afforded 15 (70% yield); m.p. 140-141° (from CCl $_4$); [α] $_D$ = 6.5° (c = 0.9 in CHCl $_3$). Anal. Calcd. for C $_1$ 6 H 20 N 406: C, 52.74; H, 5.53; N, 15.38. Found: C, 52.81; H, 5.49; N, 15.48. UV (λ max, CHCl $_3$) 266 nm (ϵ = 14500). CI MS gave significant ions at m/z: 365 (MH) $^+$, 245 (MH-2CH $_3$ COOH) $^+$, 201 (diacetylated sugar) $^+$.

Deacetylation of 15

Compound 16 was obtained by treating 15 with excess of a solution of concentrated ammonia/MeOH (1:1) at room temperature for 6 hrs under stirring. After removal of the solvent in vacuo the residue was dissolved in water and lyophilizated to give pure 16 in almost quantitative yield; m.p. 99-103° (from CHCl₃); $[\alpha]_D$ 35.6° (c= 1 in MeOH). Anal. Calcd. for $C_{12}^H_{16}^N_4^O_4$: C, 51.42; H, 5.75; N, 19.99. Found: C, 51.46; H, 5.77; N, 20.03. UV (λ_{max} in MeOH) 274 nm (ϵ = 7000), 252 (4600). FAB MS gave significant ions at m/z: 281 (MH)⁺, 165 (M-sugar residue + 2H)⁺.

Synthesis of triazo[4,3-c] pyrimidine nucleosides 17 (18)

At 200 mg of the 4-hydrazinopyrimidine nucleoside $\underline{4}$ ($\underline{6}$) in dry pyridine (6 ml), 3 ml of acetic formic anhydride were added and the mixture was kept at 0° for 3 hrs. TLC analysis (silica gel, eluent CHCl $_3$ /MeOH 95:5) indicated that the starting compound had been completely converted into a single product. After removal of the solvent in vacuo the solid residue was treated with excess of a solution of concentrated ammonia/MeOH (3:2) for 6 hrs under stirring. The crude mixture, dried in vacuo, was chromatographed by PLC (silica gel 0.5 mm, eluent CHCl $_3$ /MeOH 8:2); the band (UV

light, $R_{\rm f}$ 0.5 for compound 17, $R_{\rm f}$ 0.45 for compound 18) eluted with CHCl $_3$ /MeOH (1:1) afforded the desired products 17: (90 % yield); m.p. 161-162° (from EtOH); $\left[\alpha\right]_{\rm D} = 42.7^{\circ}$ (c = 1 in MeOH). Anal. Calcd. for : $C_{11}H_{14}N_4O_4$: C, 49.62; H, 5.30; N, 21.04. Found : C, 49.71; H, 5.30; N, 21.06. UV ($\lambda_{\rm max}$ in MeOH) 274 nm (ϵ = 8800), 254 (6600). FAB MS gave significant ions at m/z : 267 (MH) $^+$, 151 (M-sugar residues+2H) $^+$.

18: (86 % yield); m.p. 165-169° (from EtOH); $[\alpha]_D = 46.5^\circ$ (c = 1.1 in MeOH). Anal. Calcd. for $C_{10}^H_{12}^N_4^O_4$: C, 47.62; H, 4.80; N, 22.22. Found: C, 47.48; H, 4.87; N, 22.10. UV (λ_{max} in MeOH) 268 nm (ϵ = 4500), 252 nm (s). FAB MS gave significant ions at m/z : 253 (MH)⁺, 137 (M-sugar residue + 2H)⁺.

ACKNOWLEDGEMENTS

This work was supported by: CNR, Progetto Finalizzato Chimica Fine e Secondaria and M.P.I. Mass spectral data were provided by "Servizio di Spettrometria di Massa del CNR e dell'Università di Napoli".

REFERENCES

- 1) Targets for the Design of Antiviral Agents, E. De Clercq, R.T. Walker, Eds.; Plenum Press; New York (1984).
- 2) P.S. Ritch and R.I. Glazer, <u>Developments in Cancer Chemotherapy</u>, R.I. Glazer, Eds.; CRC Press.Inc.; Ohio, (1984).
- 3) <u>Nucleoside Analogues.</u> <u>Chemistry, Biology and Medical Application</u>, R.T. Walker, E. De Clercq and F. Eckstein, Eds.; Plenum Press; New York and London (1979).

4) L. Mayol, G. Piccialli, M. Rossi and C. Santacroce, <u>Gazz</u>. Chim. Ital., 113, 863 (1983).

- 5) L. De Napoli, L. Mayol, G. Piccialli, M. Rossi and C. Santacroce, J. Heterocycl. Chem., 23, 1401 (1986).
- 6) S. Bartolucci, L. De Napoli, L. Mayol, G. Piccialli, M. Rossi and C. Santacroce, <u>J. Heterocycl.Chem.</u>, in press.
- 7) A.F. Maggio, M. Lucas. J.L. Barascut and J.L. Imbach, <u>Te-</u>trahedron Letters, 25, 3195 (1984).
- 8) A.F. Maggio, M. Lucas, J.L. Barascut, A. Pompon and J.L. Imbach, Nouv. J. Chim., 10, 643 (1986).
- 9) A.F. Maggio, A. Pompon, M. Lucas, J.L. Barascut and J.L. Imbach, J. Chromatogr., 436, 23 (1988).
- 10) J.A. Montgomery, Nucleosides. Nucleotides and their Biological Application, J.L. Rideout, D.W. Henry, L. Beacham III Eds.; Academic Press; New York (1983).
- 11) F. Seela, H. Driller, Nuc. Acids Res., 14, 2319 (1986).
- 12) J.W. Bodnar, W. Zempsky, D. Warder, C. Bergson and D.C.
 Ward, J. Biol. Chem., 253, 15206 (1983).

Received June 28, 1988.